Dr. Trevanne Matthews Hew, MD
What this data tells you about Dr. Matthews Hew
Dr. Trevanne Matthews Hew is a medical oncology in Jacksonville, FL, with 14 years in practice. Based on federal Medicare data, Dr. Matthews Hew performed 56,719 Medicare services across 2,078 unique beneficiaries.
Between the years covered by Open Payments, Dr. Matthews Hew received a total of $909 from 10 pharmaceutical and/or device companies across 15 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Matthews Hew is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 9,600 | $39 | $183 |
| Filgrastim injection (Nivestym) for white blood cells | 7,440 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) | 6,300 | $0 | $1 |
| Iron infusion (Feraheme) | 6,120 | $0 | $2 |
| Nivolumab injection (Opdivo) | 4,380 | $24 | $110 |
| Daratumumab injection (Darzalex) | 4,140 | $36 | $189 |
| Oxaliplatin chemotherapy injection | 3,800 | $0 | $1 |
| Injection, paclitaxel protein-bound particles, 1 mg | 2,300 | $9 | $51 |
| Paclitaxel chemotherapy injection | 2,010 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 1,920 | $18 | $90 |
| Dexamethasone injection (steroid) | 1,518 | $0 | $3 |
| Injection, carfilzomib, 1 mg | 1,420 | $36 | $176 |
| Anti-nausea injection (ondansetron/Zofran) | 996 | $0 | $4 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 895 | $22 | $185 |
| Injection, bortezomib, 0.1 mg | 735 | $3 | $9 |
| Injection of additional new drug or substance into vein | 293 | $12 | $216 |
| Anti-nausea injection (Aloxi/palonosetron) | 290 | $1 | $9 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 221 | $3 | $37 |
| Administration of chemotherapy into vein, 1 hour or less | 219 | $96 | $869 |
| Office visit, established patient (30-39 min) | 163 | $93 | $450 |
| Injection, carboplatin, 50 mg | 162 | $2 | $30 |
| Collection of blood sample from implanted device | 140 | $18 | $135 |
| Injection, leucovorin calcium, per 50 mg | 138 | $3 | $22 |
| Injection, fluorouracil, 500 mg | 138 | $2 | $27 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 118 | $129 | $507 |
| Injection, magnesium sulfate, per 500 mg | 100 | $1 | $18 |
| Drug injection, under skin or into muscle | 94 | $11 | $102 |
| Office visit, established patient, complex (40-54 min) | 86 | $137 | $604 |
| Infusion into a vein for hydration, each additional hour | 81 | $10 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 78 | $22 | $233 |
| Infusion, normal saline solution , 1000 cc | 71 | $2 | $82 |
| Administration of additional new drug or substance into vein, 1 hour or less | 69 | $47 | $446 |
| New patient office visit, complex (60-74 min) | 64 | $155 | $891 |
| Office visit, established patient (20-29 min) | 63 | $65 | $296 |
| Injection, cisplatin, powder or solution, 10 mg | 63 | $2 | $38 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 58 | $54 | $352 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 55 | $24 | $200 |
| Administration of chemotherapy into vein, each additional hour | 48 | $22 | $212 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 47 | $49 | $426 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 47 | $16 | $154 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 43 | $1 | $75 |
| New patient office visit (45-59 min) | 41 | $114 | $707 |
| Injection, diphenhydramine hcl, up to 50 mg | 37 | $1 | $37 |
| Infusion into a vein for hydration, 31-60 minutes | 25 | $23 | $345 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 22 | $15 | $143 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 22 | $128 | $993 |
| Injection of drug or substance into vein | 20 | $27 | $600 |
| Administration of additional new drug or substance into vein using push technique | 16 | $42 | $370 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $16 | $96 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (91%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Matthews Hew is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Matthews Hew experienced with pembrolizumab injection (keytruda)?
Does Dr. Matthews Hew receive payments from pharmaceutical companies?
How do Dr. Matthews Hew's costs compare to other medical oncologys in Jacksonville?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology